ATRX and neuroblastoma: We aggregated data from 702 neuroblastomas (679 diagnosis and 23 relapsed), which were profiled by whole genome sequencing (WGS, n = 205), whole exome sequencing (WES, n = 539), and/or RNA-Seq (n = 169); 45% of the samples (n = 317) were new data generated from COG for this study (Supplementary Fig. 1a; the 317 samples were sequenced by WES plus targeted sequencing of the entire ATRX gene to detect structural variants along with sequence mutations).